ConductScience.org, home

Paper40568833

Sorafenib with or without co-interventions for hepatocellular carcinoma.

Chen S and 4 others. Cochrane Database Syst Rev, 2025. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Sorafenib with or without co-interventions for hepatocellular carcinoma. Papers, record 40568833. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40568833

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Sorafenib with or without co-interventions for hepatocellular carcinoma.
PubMed
Journal
Cochrane Database Syst Rev
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2025-07-28
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Chen SShanshan
2Liu JPJian Ping
3Li XXinyu
4Dang SShoutao
5Li WWei

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Carcinoma, HepatocellularMajor topic
Liver NeoplasmsMajor topic
SorafenibMajor topic
Adult
Humans
Randomized Controlled Trials as Topic
Systematic Reviews as Topic

Source PubMed

Download CSV of topics

References169

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133640712Sorafenib blocks the activation of the HIF-2α/VEGFA/EphA2 pathway, and inhibits the rapid growth of residual liver cancer following high-intensity focused ultrasound therapy in vivo.Pathol Res Pract2021https://conductscience.org/library/papers/33640712PubMed
234200809Is the Concurrent Use of Sorafenib and External Radiotherapy Feasible for Advanced Hepatocellular Carcinoma? A Meta-Analysis.Cancers (Basel)2021https://conductscience.org/library/papers/34200809PubMed
334680278In the Era of Systemic Therapy for Hepatocellular Carcinoma Is Transarterial Chemoembolization Still a Card to Play?Cancers (Basel)2021https://conductscience.org/library/papers/34680278PubMed
411776102Effect of preoperative transcatheter arterial chemoembolization on tumor cell activity in hepatocellular carcinoma.Chin Med J (Engl)2000https://conductscience.org/library/papers/11776102PubMed
529712486Hypoxia and tumor angiogenesis in the era of hepatocellular carcinoma transarterial loco-regional treatments.Future Oncol2018https://conductscience.org/library/papers/29712486PubMed
639817679Cancer statistics, 2025.CA Cancer J Clin2025https://conductscience.org/library/papers/39817679PubMed
731421157Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.J Hepatol2019https://conductscience.org/library/papers/31421157PubMed
828983565The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015.JAMA Oncol2017https://conductscience.org/library/papers/28983565PubMed
925260315Liver resection for HCC: patient's selection and controversial scenarios.Best Pract Res Clin Gastroenterol2014https://conductscience.org/library/papers/25260315PubMed
1018650514Sorafenib in advanced hepatocellular carcinoma.N Engl J Med2008https://conductscience.org/library/papers/18650514PubMed
1123715941Sorafenib: from literature to clinical practice.Ann Oncol2013https://conductscience.org/library/papers/23715941PubMed
1229327594Liver Resection and Surgical Strategies for Management of Primary Liver Cancer.Cancer Control2018https://conductscience.org/library/papers/29327594PubMed
1335999370Thermal ablation versus hepatic resection for colorectal cancer with synchronous liver metastases: a propensity score matching study.Eur Radiol2022https://conductscience.org/library/papers/35999370PubMed
1425223462Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study.Oncologist2014https://conductscience.org/library/papers/25223462PubMed
1531801872Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.Gut2020https://conductscience.org/library/papers/31801872PubMed
1630342970Increased risks for random errors are common in outcomes graded as high certainty of evidence.J Clin Epidemiol2019https://conductscience.org/library/papers/30342970PubMed
1723474115Sorafenib enhances radiation-induced apoptosis in hepatocellular carcinoma by inhibiting STAT3.Int J Radiat Oncol Biol Phys2013https://conductscience.org/library/papers/23474115PubMed
1834112190A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection.World J Surg Oncol2021https://conductscience.org/library/papers/34112190PubMed
1936737488Comparison of the efficacy and safety of selective internal radiotherapy and sorafenib alone or combined for hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis.Clin Exp Med2023https://conductscience.org/library/papers/36737488PubMed
2019095497Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.Lancet Oncol2009https://conductscience.org/library/papers/19095497PubMed

See all 169 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42774851Sorafenib-loaded porphyrin-phospholipid liposomes for enhanced chemophototherapy in hepatocellular carcinoma.RSC Adv2026https://conductscience.org/library/papers/42774851PubMed
42350821Safranal improves the anticancer efficacy of sorafenib via transcriptomic reprogramming and metabolomic changes in a rat model of diethylnitrosamine-induced cirrhosis-hepatocellular carcinoma.Naunyn Schmiedebergs Arch Pharmacol2026https://conductscience.org/library/papers/42350821PubMed
42327777Comparative efficacy and safety of first-line treatments for advanced hepatocellular carcinoma: a Bayesian network meta-analysis.Front Immunol2026https://conductscience.org/library/papers/42327777PubMed
41991725The tumor suppressor NDRG2 promotes ACC1 proteasomal degradation and inhibits de novo lipogenesis in hepatocellular carcinoma.Mol Biomed2026https://conductscience.org/library/papers/41991725PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40568833

GET https://conductscience.org/api/papers/v1/40568833/references?page=2